Poolbeg Pharma commences trading on OTCQB Market in the United States
Poolbeg Pharma PLC (AIM:POLB) Commencement of trading on US OTCQB market
Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
Poolbeg Pharma PLC (AIM:POLB) 2021 Annual Report and 2022 AGM Notice
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and
Braveheart Inv Group (AIM: BRH) Operational update
Braveheart Investment Group plc (AIM: BRH), provides the following update on its investment portfolio and strategy.
Poolbeg Pharma PLC (POLB.L) Confirmation of vaccine platform licence execution
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Braveheart Inv Group (BRH.L) Operational update on Paraytec
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio. Recent upgrades to the CX300 instrument indicate a
Poolbeg Pharma PLC (POLB.L) Exclusive license of RNA-based immunotherapy asset
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
Poolbeg Pharma (LSE:POLB) Year in (Video) Review 2021
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan
Share Talk catches up with CEO Jeremy Skillington, Poolbeg Pharma (LON: POLB) Interview
Share Talk caught up with our CEO to discuss yesterday’s announcement on #POLB’s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full
Poolbeg Pharma (POLB.L) agrees terms to develop an oral vaccine delivery platform
16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet,
Poolbeg Pharma PLC (POLB.L) signs option for new vaccine candidate
Poolbeg signs Option Agreement with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets
